Publications & Posters

NPJ Viruses | August 6, 2024

Vaccination with ancestral SARS-CoV-2 spike adjuvanted with TLR agonists provides cross-protection against XBB.1

Frontiers in Immunology | July 23, 2024

Intranasal administration of a synthetic TLR4 agonist INI-2004 significantly reduces allergy symptoms following therapeutic administration in a murine model of allergic sensitization

NPJ Vaccines | June 6, 2024

Vaccination with Mincle agonist UM-1098 and mycobacterial antigens induces protective Th1 and Th17 responses

ACS Applied Bio Materials | June 4, 2024

Promotion of Th17 polarized immunity via co-delivery of Mincle agonist and Tuberculosis antigen using silica nanoparticles

Pharmaceutics | January 13, 2024

Co-delivery of a novel lipidated TLR7/8 agonist and hemagglutinin-based influenza antigen using silica nanoparticles promotes enhanced immune responses

Vaccines | December 23, 2023

Co-delivery of novel synthetic TLR4 and TLR7/8 ligands adsorbed to aluminum salts promotes Th1-mediated immunity against poorly immunogenic SARS-CoV-2 RBD

Journal of Medicinal Chemistry | October 17, 2023

Diamino allose phosphates: Novel, potent, and highly stable Toll-like receptor 4 agonists

Bioconjugate Chemistry | September 27, 2023

Self-adjuvanting TLR7/8 agonist and fentanyl hapten co-conjugate achieves enhanced protection against fentanyl challenge

NPJ Vaccines | July 24, 2023

A TLR7/8 agonist increases efficacy of anti-fentanyl vaccines in rodent and porcine models

B. Crouse et al.
NPJ Vaccines | July 10, 2023

A lipidated TLR7/8 adjuvant enhances the efficacy of a vaccine against fentanyl in mice

S.M. Miller et al.
Pharmaceutics | July 12, 2022

Using Dual Toll-like Receptor Agonism to Drive Th1-BiasedResponse in a Squalene- andα-Tocopherol-ContainingEmulsion for a More Effective SARS-CoV-2 Vaccine

SITC | August 11, 2022

A novel immunostimulatory TLR7/8 agonist is curative as a monotherapy in Lewis Lung Carcinoma and synergizes with anti-PD-1 in B16F10 and MC38 tumor models

Journal of Immunology | May 2, 2022

Intranasal administration of a novel synthetic TLR4 agonist suppresses allergen-specific Th2 responses in mice